Catriona Yale - Sep 9, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Development Officer
Signature: /s/ Jonathan Young, Attorney-in-Fact
Stock symbol: AKRO
Transactions as of: Sep 9, 2022
Transactions value $: $9,251
Form type: 4
Date filed: 9/13/2022, 09:15 PM
Previous filing: Dec 10, 2021
Next filing: Sep 15, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Award	$9.25K	+1.15K	+0.95%	$8.03^*	122K	Jun 30, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Award	$0	+29.1K		$0.00	29.1K	Sep 9, 2022	Common Stock	29.1K	$21.10	Direct	F2
transaction	AKRO	Stock Option (Right to Buy)	Award	$0	+29.1K	+100%	$0.00	58.1K	Sep 13, 2022	Common Stock	29.1K	$21.10	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired on June 30, 2022 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option.
F3	On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option.